Compare W W Grainger Inc (GWW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs TG Therapeutics Inc — how do they compare? W W Grainger Inc trades at $1,402.78 (market cap $64.75B), while TG Therapeutics Inc trades at $54.98 (market cap $8.64B). The key difference: W W Grainger Inc is far larger — about 7.5× TG Therapeutics Inc's market cap, and W W Grainger Inc pays a 0.68% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GWW | TGTX | |
|---|---|---|
Market Cap | $64.75B | $8.64B |
Sector | Technology | Health |
52-Week High | $1.39K | $59.06 |
52-Week Low | $918.18 | $26.39 |
Enterprise Value | $66.84B | $8.88B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,398.30, up 1.99% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q1 2026 earnings of $11.65 per share, beating estimates, and raised its full-year guidance. Revenue growth and profitability remain solid, with a net income margin of 9.7% and ROE of 48.1% for 2025. Recent news highlights its inclusion in high-quality dividend and momentum stock lists, reflecting positive market recognition.
The outlook for GWW is positive, driven by earnings beats and upward guidance revisions, though valuation multiples like a P/E of 36.88 suggest premium pricing. Risks include competitive pressures in the industrial services sector and reliance on MRO market demand. Analyst consensus is cautious with a hold-heavy rating, but the average price target of $1,260 implies modest upside potential from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
